Drugs / JR-441
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06095388 | Oct 2023 → Oct 2029 expected | mucopolysaccharidosis type 3A | JCR Pharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JR-441 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06095388 ↗ |
| Route | Intravenous | “IV infusion” NCT06095388 ↗ |